Galapagos and Gilead Sciences have suspended the worldwide ISABELA Phase 3 program investigating the potential of oral ziritaxestat (GLPG1690) to treat people with idiopathic pulmonary fibrosis (IPF). The decision to halt the program, which includes two identical Phase 3 trials — ISABELA 1 (NCT03711162) and ISABELA 2…
The U.S. Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for ImmunoMet Therapeutics‘ treatment candidate for idiopathic pulmonary fibrosis (IPF), IM156. The decision grants ImmunoMet permission to open studies of the therapy in people in the U.S. “FDA clearance of an IND for…
The U.S. Food and Drug Administration (FDA) has accepted and granted priority review to an application for Esbriet (pirfenidone) as a treatment for unclassifiable interstitial lung disease (UILD). The supplemental new drug application was submitted by Genentech, Esbriet’s developer and a member of the Roche Group, based on…
Scores of virtual events are afoot around the world to mark Rare Disease Day 2021 on Feb. 28. The activities are focused on heightening awareness about rare diseases and the hundreds of millions of individuals they are thought to affect. Patients, caregivers, and advocates worldwide will sport denim ribbons and…
Lung cancer is more likely in people with idiopathic pulmonary fibrosis (IPF) than the public at large, and these patients should be given regular chest scans for its presence, a study reports. Routine use of high-resolution computed tomography (HRCT) chest scans is particularly important because lung cancer lowers an…
Three Lakes Foundation and the Mayo Clinic have partnered to help people be more aware of pulmonary fibrosis (PF) symptoms, and to be diagnosed earlier in the disease process should they have them. The venture’s ultimate goal is a way of making a remote diagnosis possible, so…
A researcher at the Fred Hutchinson Cancer Research Center received the first $50,000 award of a new funding program jointly developed by the center and the Washington Research Foundation (WRF) to support the development of a new screening method to identify emerging therapies for idiopathic pulmonary fibrosis (IPF).
While progress was made last year on newborn screening and other policy issues critical to rare disease patients, a “State Report Card” argues that many concerns — notably out-of-pocket costs for prescription medicines and access to affordable comprehensive care — still need attention. Those were the findings of the…
The European Idiopathic Pulmonary Fibrosis (IPF) and Related Disorders Federation (EU-IPFF) is welcoming patients, clinicians, researchers, industry representatives, and policymakers to register for a three-day virtual summit  regarding pulmonary fibrosis (PF) and other interstitial lung diseases (ILDs). The European PF Patient Summit, which will be held online April…
People with idiopathic pulmonary fibrosis (IPF) in poorer health are less likely than healthier patients to tolerate more than one year of treatment with Ofev (nintedanib), and benefit less from the therapy than those able to continue with its use, a small real-world study reports. Side effects that…
Get regular updates to your inbox.
